BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19728852)

  • 1. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
    Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
    Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
    Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
    J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.
    Levinson SS
    Ann Clin Lab Sci; 2010; 40(4):348-53. PubMed ID: 20947809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
    Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
    Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population.
    Abadie JM; Bankson DD
    Ann Clin Lab Sci; 2006; 36(2):157-62. PubMed ID: 16682511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
    Wolff F; Thiry C; Willems D
    Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
    Campbell JP; Heaney JL; Shemar M; Baldwin D; Griffin AE; Oldridge E; Goodall M; Afzal Z; Plant T; Cobbold M; Jefferis R; Jacobs JF; Hand C; Drayson MT
    Clin Chem Lab Med; 2017 Mar; 55(3):424-434. PubMed ID: 27505089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.
    Hoedemakers RM; Pruijt JF; Hol S; Teunissen E; Martens H; Stam P; Melsert R; Te Velthuis H
    Clin Chem Lab Med; 2011 Nov; 50(3):489-95. PubMed ID: 22098433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study.
    Cotten SW; Shajani-Yi Z; Cervinski MA; Voorhees T; Tuchman SA; Korpi-Steiner N
    Clin Biochem; 2018 Aug; 58():100-107. PubMed ID: 29885308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in the management of multiple myeloma introduced by serum free light chain measurement].
    Fuchida S; Shimazaki C
    Nihon Rinsho; 2011 Dec; 69(12):2267-73. PubMed ID: 22242331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of serum free light chain levels in healthy adults immediately after marathon running.
    Campbell JP; Eijsvogels TM; Wang Y; Hopman MT; Jacobs JF
    Clin Chem Lab Med; 2016 Mar; 54(3):459-65. PubMed ID: 26351935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Free Light Chain Assay: Shift Toward a Higher κ/λ Ratio.
    Rindlisbacher B; Schild C; Egger F; Bacher VU; Pabst T; Leichtle A; Andres M; Sédille-Mostafaie N
    J Appl Lab Med; 2020 Jan; 5(1):114-125. PubMed ID: 32445339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
    Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
    Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.